Intravenous etidronate in the management of malignant hypercalcemia

E. Ryzen, R. R. Martodam, M. Troxell, A. Benson, A. Paterson, K. Shepard, R. Hicks

Research output: Contribution to journalArticle

Abstract

The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2, 3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3 ± 2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non-small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.

Original languageEnglish (US)
Pages (from-to)449-452
Number of pages4
JournalArchives of Internal Medicine
Volume145
Issue number3
DOIs
StatePublished - May 29 1985

Fingerprint

Etidronic Acid
Hypercalcemia
Therapeutics
Serum
Multiple Myeloma
Non-Small Cell Lung Carcinoma
Reaction Time
Creatinine
Neoplasms
Reference Values
Breast Neoplasms
Calcium

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Ryzen, E., Martodam, R. R., Troxell, M., Benson, A., Paterson, A., Shepard, K., & Hicks, R. (1985). Intravenous etidronate in the management of malignant hypercalcemia. Archives of Internal Medicine, 145(3), 449-452. https://doi.org/10.1001/archinte.145.3.449
Ryzen, E. ; Martodam, R. R. ; Troxell, M. ; Benson, A. ; Paterson, A. ; Shepard, K. ; Hicks, R. / Intravenous etidronate in the management of malignant hypercalcemia. In: Archives of Internal Medicine. 1985 ; Vol. 145, No. 3. pp. 449-452.
@article{ea9f8178c6664c3bbeb281276f6217ee,
title = "Intravenous etidronate in the management of malignant hypercalcemia",
abstract = "The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2, 3, or 4 consecutive days. The serum calcium level in 19 (73{\%}) of 26 patients returned to the normal range with a mean response time of 3 ± 2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non-small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.",
author = "E. Ryzen and Martodam, {R. R.} and M. Troxell and A. Benson and A. Paterson and K. Shepard and R. Hicks",
year = "1985",
month = "5",
day = "29",
doi = "10.1001/archinte.145.3.449",
language = "English (US)",
volume = "145",
pages = "449--452",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "3",

}

Ryzen, E, Martodam, RR, Troxell, M, Benson, A, Paterson, A, Shepard, K & Hicks, R 1985, 'Intravenous etidronate in the management of malignant hypercalcemia', Archives of Internal Medicine, vol. 145, no. 3, pp. 449-452. https://doi.org/10.1001/archinte.145.3.449

Intravenous etidronate in the management of malignant hypercalcemia. / Ryzen, E.; Martodam, R. R.; Troxell, M.; Benson, A.; Paterson, A.; Shepard, K.; Hicks, R.

In: Archives of Internal Medicine, Vol. 145, No. 3, 29.05.1985, p. 449-452.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravenous etidronate in the management of malignant hypercalcemia

AU - Ryzen, E.

AU - Martodam, R. R.

AU - Troxell, M.

AU - Benson, A.

AU - Paterson, A.

AU - Shepard, K.

AU - Hicks, R.

PY - 1985/5/29

Y1 - 1985/5/29

N2 - The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2, 3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3 ± 2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non-small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.

AB - The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2, 3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3 ± 2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non-small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.

UR - http://www.scopus.com/inward/record.url?scp=0021928106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021928106&partnerID=8YFLogxK

U2 - 10.1001/archinte.145.3.449

DO - 10.1001/archinte.145.3.449

M3 - Article

C2 - 3919667

VL - 145

SP - 449

EP - 452

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 3

ER -